Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVOCAT study
NL-OMON26811Phase 3Recruiting
- Sponsor
- STIWU: Stichting ter bevordering van het Wetenschappelijk Urologisch onderzoek (Foundation for the stimulation of Scientific Urological Research.)
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Bicalutamide monotherapy with Bicalutamide + dutasteride (2 arms). Primary endpoint: PSA progression after 3 years of study treatment. Started Mar 2006; status: recruiting.
02
Drugs
bicalutamidedutasteride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON26811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26811.